Advertisement
DMAC vs OBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a StrongBuy and OBIO is a Hold.
Momentum Indicator for DMAC turns positive, indicating new upward trend
DMAC saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 81 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for DMAC just turned positive on October 22, 2026. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +15.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 218 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 125 of 159 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for DMAC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
DMAC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 34 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.716) is normal, around the industry mean (2.788). P/E Ratio (-12.556) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
OBIO saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for OBIO moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 45 of the 56 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for OBIO turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 32 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.
OBIO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on OBIO as a result. In 70 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The 10-day moving average for OBIO crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in 164 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
OBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 133 of 181 cases where OBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.481) is normal, around the industry mean (2.788). P/E Ratio (-6.690) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (11.198) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DMAC | OBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 34 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 36 | |
P/E GROWTH RATING 1..100 | 81 | 91 | |
SEASONALITY SCORE 1..100 | 85 | 22 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DMAC's Valuation (74) in the Biotechnology industry is in the same range as OBIO (83) in the null industry. This means that DMAC’s stock grew similarly to OBIO’s over the last 12 months.
DMAC's Profit vs Risk Rating (34) in the Biotechnology industry is significantly better than the same rating for OBIO (100) in the null industry. This means that DMAC’s stock grew significantly faster than OBIO’s over the last 12 months.
DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as OBIO (100) in the null industry. This means that DMAC’s stock grew similarly to OBIO’s over the last 12 months.
DMAC's Price Growth Rating (35) in the Biotechnology industry is in the same range as OBIO (36) in the null industry. This means that DMAC’s stock grew similarly to OBIO’s over the last 12 months.
DMAC's P/E Growth Rating (81) in the Biotechnology industry is in the same range as OBIO (91) in the null industry. This means that DMAC’s stock grew similarly to OBIO’s over the last 12 months.
| DMAC | OBIO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | N/A |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 73% |
| Advances ODDS (%) | 3 days ago 84% | 9 days ago 76% |
| Declines ODDS (%) | 8 days ago 81% | 4 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DMAC’s FA Score shows that 0 FA rating(s) are green while OBIO’s FA Score has 0 green FA rating(s).
- DMAC’s FA Score: 0 green, 5 red.
- OBIO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DMAC’s TA Score shows that 5 TA indicator(s) are bullish while OBIO’s TA Score has 5 bullish TA indicator(s).
- DMAC’s TA Score: 5 bullish, 4 bearish.
- OBIO’s TA Score: 5 bullish, 4 bearish.
Price Growth
DMAC (@Biotechnology) experienced а -5.04% price change this week, while OBIO (@Biotechnology) price change was -7.72% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.63%. For the same industry, the average monthly price growth was -4.05%, and the average quarterly price growth was -15.18%.
Reported Earning Dates
DMAC is expected to report earnings on Nov 11, 2026.
OBIO is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+7.63% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement